Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.

von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R.

Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.

PMID:
30630778
2.

Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; for TBNET.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):379-386. doi: 10.1164/rccm.201710-2141OC.

PMID:
29509468
3.

Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?

Balabanova Y, Fiebig L, Ignatyeva O, Riekstina V, Danilovits M, Jaama K, Davidaviciene E, Radiulyte B, Popa CM, Nikolayevskyy V, Drobniewski F.

Thorax. 2017 Sep;72(9):850-852. doi: 10.1136/thoraxjnl-2016-209841. Epub 2017 Feb 16.

PMID:
28209653
4.

Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBNET.

N Engl J Med. 2016 Sep 15;375(11):1103-5. doi: 10.1056/NEJMc1603274. No abstract available.

5.

Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.

Gillard P, Yang PC, Danilovits M, Su WJ, Cheng SL, Pehme L, Bollaerts A, Jongert E, Moris P, Ofori-Anyinam O, Demoitié MA, Castro M.

Tuberculosis (Edinb). 2016 Sep;100:118-127. doi: 10.1016/j.tube.2016.07.005. Epub 2016 Jul 21.

6.

Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?

Balabanova Y, Ignatyeva O, Fiebig L, Riekstina V, Danilovits M, Jaama K, Davidaviciene E, Radiulyte B, Popa CM, Nikolayevskyy V, Drobniewski F.

Thorax. 2016 Sep;71(9):854-61. doi: 10.1136/thoraxjnl-2015-207638. Epub 2016 Mar 24.

7.

Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.

Tupasi T, Gupta R, Danilovits M, Cirule A, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Gentry LM, Geiter LJ, Wells CD.

Bull World Health Organ. 2016 Feb 1;94(2):147-52. doi: 10.2471/BLT.15.154997. Epub 2015 Nov 17.

8.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

9.

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study.

Stagg HR, Brown J, Ibraim E, Riekstiņa V, Viiklepp P, Cīrule A, Cocei H, Danilovitš M, Dravniece G, Jackson C, White PJ.

PLoS One. 2015 Nov 11;10(11):e0142425. doi: 10.1371/journal.pone.0142425. eCollection 2015.

10.

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.

Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators, Lancaster J, Odendaal R, Diem L, Perez TC, Gler T, Tan K, Bonilla C, Jave O, Asencios L, Yale G, Suarez C, Walker AT, Norvaisha I, Skenders G, Sture I, Riekstina V, Cirule A, Sigman E, Cho SN, Cai Y, Eum S, Lee J, Park S, Jeon D, Shamputa IC, Metchock B, Kuznetsova T, Akksilp R, Sitti W, Inyapong J, Kiryanova EV, Degtyareva I, Nemtsova ES, Levina K, Danilovits M, Kummik T, Lei YC, Huang WL, Erokhin VV, Chernousova LN, Andreevskaya SN, Larionova EE, Smirnova TG.

Clin Infect Dis. 2016 Feb 15;62(4):418-430. doi: 10.1093/cid/civ910. Epub 2015 Oct 27.

11.

A four-year nationwide molecular epidemiological study in Estonia: risk factors for tuberculosis transmission.

Toit K, Altraja A, Acosta CD, Viiklepp P, Kremer K, Kummik T, Danilovitš M, Van den Bergh R, Harries AD, Supply P.

Public Health Action. 2014 Oct 21;4(Suppl 2):S34-40. doi: 10.5588/pha.14.0045.

12.

Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries.

Ignatyeva O, Balabanova Y, Nikolayevskyy V, Koshkarova E, Radiulyte B, Davidaviciene E, Riekstina V, Jaama K, Danilovits M, Popa CM, Drobniewski FA.

Tuberculosis (Edinb). 2015 Sep;95(5):581-8. doi: 10.1016/j.tube.2015.05.018. Epub 2015 Jun 24.

PMID:
26164355
13.

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M.

Lancet Respir Med. 2015 Mar;3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3. Epub 2015 Feb 26.

14.

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD.

Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.

15.

Delamanid for multidrug-resistant pulmonary tuberculosis.

Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD.

N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.

16.

European union standards for tuberculosis care.

Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K, Aksamit T, Cirillo DM, Danilovits M, Dara M, Dheda K, Dinh-Xuan AT, Kluge H, Lange C, Leimane V, Loddenkemper R, Nicod LP, Raviglione MC, Spanevello A, Thomsen VØ, Villar M, Wanlin M, Wedzicha JA, Zumla A, Blasi F, Huitric E, Sandgren A, Manissero D.

Eur Respir J. 2012 Apr;39(4):807-19. doi: 10.1183/09031936.00203811.

17.

Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.

Floyd K, Hutubessy R, Kliiman K, Centis R, Khurieva N, Jakobowiak W, Danilovits M, Peremitin G, Keshavjee S, Migliori GB.

Eur Respir J. 2012 Jul;40(1):133-42. doi: 10.1183/09031936.00169411. Epub 2012 Feb 23.

18.

Multidrug-resistant tuberculosis management in resource-limited settings.

Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, Hollo V, Jaramillo E, Leimane V, Mitnick CD, Mukherjee JS, Nunn P, Pasechnikov A, Tupasi T, Wells C, Raviglione MC.

Emerg Infect Dis. 2006 Sep;12(9):1389-97.

19.

Spread of drug-resistant pulmonary tuberculosis in Estonia.

Krüüner A, Hoffner SE, Sillastu H, Danilovits M, Levina K, Svenson SB, Ghebremichael S, Koivula T, Källenius G.

J Clin Microbiol. 2001 Sep;39(9):3339-45.

Supplemental Content

Loading ...
Support Center